PROTECTNCT07647029
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Eligibility criteria expanded, about 27 words
- Primary endpoints: details revised at 1 of 1 entry
- Study sites: 0 to 1
- Start date changed from estimate of May 28, 2026 to Jul 16, 2026
- Secondary endpoints: details revised at 2 of 6 entries
- Publications: details revised at 7 of 7 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of grade ≥2 thrombocytopenia (PLT < 75×10⁹/L)
Timeframe: At the end of Cycle 2 (each cycle ≥21 days)
Secondary (6)
Duration of grade ≥2 thrombocytopenia (PLT < 75×10⁹/L)
Incidence and duration of grade ≥3 thrombocytopenia (PLT < 50×10⁹/L)
Proportion of patients who successfully completed two chemotherapy cycles without thrombocytopenia-related modifications to subsequent antineoplastic therapy
Proportion of patients without rescue therapy for thrombocytopenia (e.g., platelet transfusion, interleukin-11, recombinant human thrombopoietin)
Nadir and peak platelet counts
Show 1 moreShow less
Incidence of adverse events
Arms and interventions
No prophylactic use of hetrombopagNo intervention
No prophylactic use of hetrombopag
Continuous Hetrombopag for 2 CyclesExperimental
Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 of the first chemotherapy cycle (C1D1) continuously until the end of the second chemotherapy cycle
Cyclic 14-day Hetrombopag for 2 CyclesExperimental
Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 (C1D1) to Day 14 (C1D14) of the first chemotherapy cycle; the dosage and administration schedule in the second chemotherapy cycle were identical to those in the first cycle
Drugs: Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
Sites
1 site in 1 country
- Fudan University Shanghai Cancer centerShanghai, Shanghai Municipality, China